Enhanced Anti-tumoral Activity of Methotrexate-human Serum Albumin Conjugated Nanoparticles by Targeting with Luteinizing Hormone-Releasing Hormone (LHRH) Peptide

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2011 Aug 17

PMID 21845098

Citations 12

Authors

Azade Taheri

Rassoul Dinarvand

Fatemeh Atyabi

Fatemeh Ahadi

Farank Salman Nouri

Mohammad Hossein Ghahremani

Seyed Nasser Ostad

Atefeh Taheri Borougeni

Pooria Mansoori

Affiliations

Soon will be listed here.

Abstract

Active targeting could increase the efficacy of anticancer drugs. Methotrexate-human serum albumin (MTX-HSA) conjugates, functionalized by luteinizing hormone-releasing hormone (LHRH) as targeting moieties, with the aim of specifically targeting the cancer cells, were prepared. Owing to the high expression of LHRH receptors in many cancer cells as compared to normal cells, LHRH was used as the targeting ligand in this study. LHRH was conjugated to MTX-HSA nanoparticles via a cross-linker. Three types of LHRH targeted nanoparticles with a mean particle size between 120-138 nm were prepared. The cytotoxicity of LHRH targeted and non-targeted nanoparticles were determined on the LHRH positive and negative cell lines. The internalization of the targeted and non-targeted nanoparticles in LHRH receptor positive and negative cells was investigated using flow cytometry analysis and fluorescence microscopy. The cytotoxicity of the LHRH targeted nanoparticles on the LHRH receptor positive cells were significantly more than non-targeted nanoparticles. LHRH targeted nanoparticles were also internalized by LHRH receptor positive cells significantly more than non-targeted nanoparticles. There were no significant differences between the uptake of targeted and non-targeted nanoparticles to the LHRH receptor negative cells. The active targeting procedure using LHRH targeted MTX-HSA nanoparticles could increase the anti-tumoral activity of MTX.

Citing Articles

Radiolabeled Human Serum Albumin Nanoparticles Co-Loaded with Methotrexate and Decorated with Trastuzumab for Breast Cancer Diagnosis.

Ekinci M, Rebelo Alencar L, Lopes A, Santos-Oliveira R, Ilem-Ozdemir D J Funct Biomater. 2023; 14(9).

PMID: 37754891 PMC: 10532481. DOI: 10.3390/jfb14090477.

Luteinizing Hormone Releasing Hormone-Targeted Cisplatin-Loaded Magnetite Nanoclusters for Simultaneous MR Imaging and Chemotherapy of Ovarian Cancer.

Vishwasrao H, Master A, Seo Y, Liu X, Pothayee N, Zhou Z Chem Mater. 2023; 28(9):3024-3040.

PMID: 37405207 PMC: 10317193. DOI: 10.1021/acs.chemmater.6b00197.

Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers.

Garrido M, Hernandez A, Vega M, Araya E, Romero C Front Endocrinol (Lausanne). 2023; 14:1143261.

PMID: 37056674 PMC: 10086188. DOI: 10.3389/fendo.2023.1143261.

Preparation and Antiproliferative Activity Evaluation of Juglone-Loaded BSA Nanoparticles.

Jahanban-Esfahlan A, Davaran S, Dastmalchi S Adv Pharm Bull. 2022; 12(4):818-827.

PMID: 36415643 PMC: 9675913. DOI: 10.34172/apb.2022.087.

Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies.

Tian H, Zhang T, Qin S, Huang Z, Zhou L, Shi J J Hematol Oncol. 2022; 15(1):132.

PMID: 36096856 PMC: 9469622. DOI: 10.1186/s13045-022-01320-5.

References

Singh Y, Palombo M, Sinko P . Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem. 2008; 15(18):1802-26. PMC: 2802226. DOI: 10.2174/092986708785132997. View

Anande N, Jain S, Jain N . Con-A conjugated mucoadhesive microspheres for the colonic delivery of diloxanide furoate. Int J Pharm. 2008; 359(1-2):182-9. DOI: 10.1016/j.ijpharm.2008.04.009. View

Bajo A, Schally A, Halmos G, Nagy A . Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res. 2003; 9(10 Pt 1):3742-8. View

Taratula O, Garbuzenko O, Kirkpatrick P, Pandya I, Savla R, Pozharov V . Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release. 2009; 140(3):284-93. PMC: 2787988. DOI: 10.1016/j.jconrel.2009.06.019. View

Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A . Cancer statistics, 2005. CA Cancer J Clin. 2005; 55(1):10-30. DOI: 10.3322/canjclin.55.1.10. View

Schally A, Nagy A . New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci. 2003; 72(21):2305-20. DOI: 10.1016/s0024-3205(03)00113-9. View

Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K . Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release. 2007; 118(1):54-8. DOI: 10.1016/j.jconrel.2006.12.012. View

Kakar S, Jennes L . Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues. Cancer Lett. 1995; 98(1):57-62. View

Janaky T, Juhasz A, Bajusz S, Csernus V, Srkalovic G, Bokser L . Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. Proc Natl Acad Sci U S A. 1992; 89(3):972-6. PMC: 48367. DOI: 10.1073/pnas.89.3.972. View

10.

Miele E, Spinelli G, Miele E, Tomao F, Tomao S . Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009; 4:99-105. PMC: 2720743. DOI: 10.2147/ijn.s3061. View

11.

Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser H . Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol. 2000; 17(5):1063-9. DOI: 10.3892/ijo.17.5.1063. View

12.

Schally A, Comaru-Schally A, Nagy A, Kovacs M, Szepeshazi K, Plonowski A . Hypothalamic hormones and cancer. Front Neuroendocrinol. 2001; 22(4):248-91. DOI: 10.1006/frne.2001.0217. View

13.

Chuang V, Kragh-Hansen U, Otagiri M . Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res. 2002; 19(5):569-77. DOI: 10.1023/a:1015396825274. View

14.

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A . Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 12(4):1317-24. DOI: 10.1158/1078-0432.CCR-05-1634. View

15.

Michaelis K, Hoffmann M, Dreis S, Herbert E, Alyautdin R, Michaelis M . Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther. 2006; 317(3):1246-53. DOI: 10.1124/jpet.105.097139. View

16.

Leuschner C, Hansel W . Targeting breast and prostate cancers through their hormone receptors. Biol Reprod. 2005; 73(5):860-5. DOI: 10.1095/biolreprod.105.043471. View

17.

Minko T, Dharap S, Pakunlu R, Wang Y . Molecular targeting of drug delivery systems to cancer. Curr Drug Targets. 2004; 5(4):389-406. DOI: 10.2174/1389450043345443. View

18.

Santhi K, Dhanaraj S, Koshy M, Ponnusankar S, Suresh B . Study of biodistribution of methotrexate-loaded bovine serum albumin nanospheres in mice. Drug Dev Ind Pharm. 2001; 26(12):1293-6. DOI: 10.1081/ddc-100102311. View

19.

Kim S, Jeong J, Lee S, Kim S, Park T . LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. Bioconjug Chem. 2008; 19(11):2156-62. DOI: 10.1021/bc800249n. View

20.

Allen T . Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002; 2(10):750-63. DOI: 10.1038/nrc903. View